Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 9/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.40 |
| ▸ | CBFB | Q13951 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4696025 | 0.80 | P2RX7 (0.59) | P2RX7 | |
| SCHEMBL4755588 | 0.79 | P2RX7 (0.57) | P2RX7 | |
| SCHEMBL4750584 | 0.78 | P2RX7 (0.59) | P2RX7 | |
| SCHEMBL5449744 | 0.78 | NPC1 (0.48) | MAPTTDP1DRD2DRD3ALDH1A1 | |
| SCHEMBL5448293 | 0.76 | P2RX7 (0.54) | P2RX7 | |
| SCHEMBL4754259 | 0.75 | P2RX7 (0.62) | P2RX7NPSR1TDP1DRD2DRD4 | |
| SCHEMBL4700388 | 0.75 | P2RX7 (0.50) | P2RX7 | |
| SCHEMBL4699709 | 0.74 | P2RX7 (0.51) | P2RX7 | |
| SCHEMBL3590729 | 0.73 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL3293536 | 0.72 | P2RX7 (0.76) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963275-A2 | P2X7 RECEPTOR ANTAGONISTS AND USES THEREOF | Abbott Laboratories (US) | 2008-09-03 | — | — | EP | claimed |
| US-20070259920-A1 | P2X7, receptor antagonists and uses thereof | ABBOTT LABORATORIES | 2007-11-08 | — | — | US | claimed |
| WO-2007056091-A2 | 2-PHENYL-2H-PYRAZ0LE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2007-05-18 | — | — | WO | claimed |
| US-20070259920-A1 | P2X7, receptor antagonists and uses thereof | ABBOTT LABORATORIES | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259920-A1 | P2X7, receptor antagonists and uses thereof | P2RX7, P2RX1, P2RX3 | P2RX7 1/4885PKM 2139/4885MAPT 3930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.